Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Synbio Tech Inc. (1295.TWO)
Kaohsiung City, TW
Synbio Tech Inc. operates as a biotechnology enterprise, primarily focusing on the development and production of probiotics and their various applications. The company also handles the marketing and distribution of several products in China, such as lactic acid bacteria (LAB) beverages, LAB powders formulated for human health, and specialized probiotic solutions for the agriculture, forestry, fishery, and animal husbandry sectors. Established on June 1, 2000, the firm maintains its principal office in Kaohsiung City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.77% | -4.03% | -9.09% | -35.15% | -46.52% | -41.18% | -42.40% | -34.61% | -34.61% | -34.61% | -34.61% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-10 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+5.0% ★ Q1'26: -8.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-2.2% Q1'26: -68.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+7.0% Q1'26: -32.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+19.1% ★ Q1'26: +6.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+7.4% ★ Q1'26: +1.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+5.6% Q1'26: +9.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×6.99× Q1'26: 8.39× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|
| Revenue |
1.04B
est: 1.03B (+0.6%)
|
1.26B
1.26B – 1.26B
+21.6% YoY
|
| EBITDA |
198.26M
est: 283.83M (-30.1%)
|
345.16M
345.16M – 345.16M
+21.6% YoY
|
| EBIT |
198.26M
est: 209.76M (-5.5%)
|
255.09M
255.09M – 255.09M
+21.6% YoY
|
| Net Income |
175.97M
est: 172.31M (+2.1%)
|
209.23M
209.23M – 209.23M
+21.4% YoY
|
| SGA |
—
est: 186.34M (-100.0%)
|
226.61M
226.61M – 226.61M
+21.6% YoY
|
| EPS |
5.29
est: 5.18 (+2.1%)
|
6.29
6.29 – 6.29
+21.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chuan-Xian Yang | GM & Corporate Director Representative | — | — |
| Hsiu-Ju Chang | Accounting Supervisor | — | — |
| Jin-Sheng Lin | Deputy General Manager | — | male |
| Kui-Ming Li | Deputy General Manager | — | — |
| San-Lian Yang | GM & Director | — | — |
| Yi-Ru Zhang | Deputy General Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1295.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
